PRELUDE THERAPEUTICS INCORPORATED - COMMON STOCK

Prelude Therapeutics Announces $25 Million Private Placement

11 Dec 2023 09:34:10 By Nasdaq GlobeNewswire

Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results

01 Nov 2023 16:10:00 By Nasdaq GlobeNewswire

Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology

01 Nov 2023 16:05:00 By Nasdaq GlobeNewswire

Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference 

14 Oct 2023 12:30:00 By Nasdaq GlobeNewswire

Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September

29 Aug 2023 08:30:00 By Nasdaq GlobeNewswire

Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

03 Aug 2023 08:00:01 By Nasdaq GlobeNewswire

Prelude Therapeutics To Participate in Jefferies Healthcare Conference

31 May 2023 08:30:00 By Nasdaq GlobeNewswire

Prelude Therapeutics Announces Pricing of Public Offering

18 May 2023 07:00:00 By Nasdaq GlobeNewswire

Prelude Therapeutics Announces Launch of Proposed Public Offering

17 May 2023 16:08:22 By Nasdaq GlobeNewswire

Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations Update

08 May 2023 08:30:00 By Nasdaq GlobeNewswire

Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in May

27 Apr 2023 08:30:00 By Nasdaq GlobeNewswire

Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference

11 Apr 2023 08:30:00 By Nasdaq GlobeNewswire

Prelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update

15 Mar 2023 08:30:00 By Nasdaq GlobeNewswire

Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic Cancers

15 Mar 2023 08:00:00 By Nasdaq GlobeNewswire

Prelude Therapeutics To Participate in Barclays Global Healthcare Conference

01 Mar 2023 08:30:00 By Nasdaq GlobeNewswire

Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences

09 Feb 2023 09:05:00 By Nasdaq GlobeNewswire

Prelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update

14 Nov 2022 08:00:02 By Nasdaq GlobeNewswire

Prelude Therapeutics Receives FDA Clearance of IND for PRT3789, a Potent and Selective First-in-Class SMARCA2 Protein Degrader

18 Oct 2022 08:00:01 By Nasdaq GlobeNewswire

Prelude Therapeutics To Participate in Upcoming HC Wainwright and Morgan Stanley Healthcare Conferences

06 Sep 2022 08:00:02 By Nasdaq GlobeNewswire

Prelude Therapeutics Announces Second Quarter 2022 Financial Results and Business Update

09 Aug 2022 08:00:01 By Nasdaq GlobeNewswire